Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours

BJU International

Volumn 104, Issue 3, 2009, Pages 340-346

  Nicolai, Nicola ^a   Necchi, Andrea ^a   Gianni, Luca ^a   Piva, Luigi ^a   Biasoni, Davide ^a   Torelli, Tullio ^a   Stagni, Silvia ^a   Milani, Angelo ^a   Pizzocaro, Giorgio ^b   Salvioni, Roberto ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b San Giuseppe Hospital   (Italy)

Author keywords

Chemotherapy; Embryonal; Germ cell; Neoplasms; Salvage therapy

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; VINBLASTINE; VINCRISTINE;

ADULT; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; GERM CELL TUMOR; HUMAN; HUMAN TISSUE; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SEMINOMA; TESTIS TUMOR; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; EPIDEMIOLOGIC METHODS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; PACLITAXEL; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVORS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 68049131610     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08453.x     Document Type: Article

References (29)

1. Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet 2006 367 : 754 65
2. Kollmannsberger C, Nichols C, Bokemeyer C. Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer 2006 106 : 1217 26
3. Broun ER, Nichols CR, Kneebone P et al. Long term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1993 117 : 124 8
4. Miller JC, Einhorn LH. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 1990 17 : 36 9
5. Motzer RJ, Bajorin DF, Schwartz LH et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994 12 : 2277 83
6. Bokemeyer C, Beyer J, Metzner B et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996 7 : 31 4
7. Bokemeyer C, Gerl A, Schoffski P et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 1999 17 : 512 6 (Pubitemid 29075236)
8. Einhorn LH, Stender MJ, Williams SD. Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 1999 17 : 509 11
9. Kollmannsberger C, Rick O, Derigs HG et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2002 20 : 2031 7 (Pubitemid 34408792)
10. Hinton S, Catalano P, Einhorn LH et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E 9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2002 20 : 1859 63
11. Kollmannsberger C, Beyer J, Liersch R et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensely pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004 22 : 108 14
12. Pectasides D, Pectasides M, Farmakis D et al. Gemcitabine and Oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors. A Phase II study. Ann Oncol 2004 15 : 493 7
13. Pectasides D, Pectasides M, Farmakis D et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study. Eur Urol 2006 46 : 216 21
14. De Giorgi U, Rosti G, Aieta M et al. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory non-seminomatous germ cell tumor. Eur Urol 2006 50 : 1032 8
15. Einhorn LH, Brames MJ, Juliar B et al. Phase II: study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol 2007 25 : 513 6
16. Bedano P, Brames M, Williams S et al. A phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumours J Clin Oncol 2006 24 : 5403 7 (Pubitemid 46623172)
17. Rowinsky EK, Gilbert MR, McGuire WP et al. Sequence of Taxol and cisplatin: a Phase I and pharmacologic study. J Clin Oncol 1991 9 : 1692 703
18. Van Moorsell J, Pinedo HM, Veerman G et al. Mechanism of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999 80 : 981 90 (Pubitemid 29233918)
19. Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumours: a multivariate analysis of prognostic variables. J Clin Oncol 1996 14 : 2638 45 (Pubitemid 26329647)
20. Nichols CR, Tricot G, Williams SD et al. Dose-intensive chemotherapy in refractory germ cell cancer. A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989 7 : 932 9
21. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981 47 : 207 11
22. International Germ Cell Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997 15 : 594 603
23. Bokemeyer C, Oechsle K, Honecker F et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 2008 19 : 448 53
24. Kondagunta GV, Bacik J, Donadio A et al. Combination of paclitaxel, ifosfamide and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005 23 : 6549 55
25. Kondagunta GV, Bacik J, Sheinfeld J et al. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 2007 25 : 85 90
26. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology; Vol I: Testicular Cancer. 2008. Available at: http://www.nccn.org. Accessed November 2008
27. Miki T, Mizutani Y, Nonomura N et al. Irinotecan plus cisplatin has substantial antitumour effect as salvage chemotherapy against germ cell tumours. Cancer 2002 95 : 1879 85
28. Mikami K, Takaha N, Shiraishi T et al. Salvage chemotherapy with paclitaxel, gemcitabine and nedaplatin (TGN) for cisplatin refractory germ cell tumors. Annual meeting of the Societè Internationale d'Urologie (SIU) Paris (Abstract), 2007
29. Murphy BR, Breeden ES, Donohue JP et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 1993 11 : 324 9